e-learning
resources
Virtual 2021
07.09.2021
Advances in asthma treatment: monoclonal antibodies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characteristics of a real world cohort of Canadians treated with benralizumab
S. Noorduyn (Mississauga, Canada), M. Hamilton (Toronto, Canada), B. Lancaster (Mississauga, Canada), A. Gendron (Montreal, Canada), L. Mbuagbaw (Hamilton, Canada), E. Penz (Saskatoon, Canada)
Source:
Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Session:
Advances in asthma treatment: monoclonal antibodies
Session type:
E-poster
Number:
3726
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Noorduyn (Mississauga, Canada), M. Hamilton (Toronto, Canada), B. Lancaster (Mississauga, Canada), A. Gendron (Montreal, Canada), L. Mbuagbaw (Hamilton, Canada), E. Penz (Saskatoon, Canada). Characteristics of a real world cohort of Canadians treated with benralizumab. 3726
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Effectiveness of favipiravir in COVID-19 patients with risk factors for mortality: A real world experience from India.
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021
Longitudinal analyses on the use of medicines in never smoker women living in two Italian areas
Source: Eur Respir J 2003; 22: Suppl. 45, 486s
Year: 2003
Experience of mycobacterium/HIV co-infection in an ethnically diverse UK population
Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis
Year: 2007
Community acquired pneumonia-a study among closed military communities of young people
Source: Eur Respir J 2002; 20: Suppl. 38, 356s
Year: 2002
Late Breaking Abstract - Identifying preventable early risk factors for asthma in Indigenous children: a population cohort study in Western Australia.
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020
Effectiveness of the pneumococcal vaccine in older adults living in the community: a prospective cohort study
Source: Eur Respir J 2005; 26: Suppl. 49, 143s
Year: 2005
Long-term trends in lung cancer incidence in non-smokers: a UK-based cohort study of 3.7 million people
Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases
Year: 2020
Risk factors for hospitalization for community-acquired pneumonia in immigrants from low-income countries and in native Italians in the province of Milan: a multicentre study
Source: Eur Respir J 2002; 20: Suppl. 38, 321s
Year: 2002
Vehicle exhausts outside home and incident asthma among adults. A prospective cohort study in three Swedish cities
Source: Annual Congress 2008 - Environmental risk factors for respiratory symptoms and COPD
Year: 2008
15-year temporal asthma patterns in a large French cohort of elderly women
Source: Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD
Year: 2012
Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands
Source: Eur Respir J, 54 (6) 1901402; 10.1183/13993003.01402-2019
Year: 2019
Control of asthma in people of ethnic minorities (from the Indian sub-continent) in the community
Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care
Year: 2009
Comparison of demographic data of patients with COPD treated in primary care by country in European Health-related Quality of Life in COPD study
Source: Annual Congress 2010 - From diagnosis to disease management in primary care
Year: 2010
Efficacy of azithromycin in a real world severe asthma cohort
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Quality of life in children with asthma in Russia: results of multi-center population study
Source: Eur Respir J 2004; 24: Suppl. 48, 382s
Year: 2004
Mortality risk in a Romanian cohort of patients hospitalised for COVID-19
Source: Virtual Congress 2021 – COVID - 19 around the globe
Year: 2021
Long-term incidence of tuberculosis among migrants according to migrant status: a cohort study
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection I
Year: 2019
Trends in asthma incidence in children: a UK population-based cohort study
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
How far is real life from COPD therapy guidelines? An observational study on 4000 patients in Italy
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept